Skip to main content
. 2021 Oct 21;13(11):1759. doi: 10.3390/pharmaceutics13111759

Figure 3.

Figure 3

The binding interactions (in black) between N3 inhibitor (in green) and the key residues (in mustard yellow) of the active site in the main protease (Mpro) of SARS-CoV-2 (PDB:6lu7). The inhibitor is divided into 5 parts (P1, P1′, P2, P3, P4, and P5).